Hanmi Pharmaceutical, 920dollar obesity drug commercialization preparations gather pace for launch this year

Hanmi Pharmaceutical (128940) said it would begin commercializing its independently developed obesity treatment this year. The company is preparing for commercialization and aims to enter the global market. The company said it was proceeding step by step with the procedures related to commercialization.

According to data from pharmaceutical market research firm IQVIA, the obesity treatment market was 2025 in 660 dollars. It was reported to have grown to 920 dollars this year. In recent years, the obesity field has been classified as a rapidly growing area of treatment in the global market.

The company noted that the wider availability of obesity treatments could affect sales of its existing obesity-related treatments. It said it would therefore also reorganize its portfolio. Portfolio reorganization involves reviewing the product lineup and sales strategy.

Hanmi Pharmaceutical said it is preparing for production and distribution alongside preparations for commercialization. The specific launch schedule and regulatory approval plans can be confirmed through company disclosures. The company has announced that it will make additional related disclosures.

The key points of Hanmi Pharmaceutical’s announcement are its plan to commercialize a new drug within the year and its portfolio realignment. The company plans to disclose updates on the progress of related procedures in stages. Investors can check the company’s disclosures for the detailed schedule.